References
- Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407
- Amgen Inc. Aranesp (darbepoetin alfa) full prescribing information. [cited July 18, 2007]; Available from: www.aranesp.com/pdf/aranesp.pi.pdf
- Amgen Inc. Epogen (erythropoetin alfa) full prescribing information. [cited July 18, 2007]; Available from: www.epogen.com/pdf/epogen_pi.pdf
- Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60
- Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960–72
- Wright JR, Ung YC, Julian JA, Pritchard KI, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027–32
- National Comprehensive Cancer Network (NCCN). Cancer-and Treatment-Related Anemia. Version 2.2005. 2005
- National Comprehensive Cancer Network (NCCN). Cancer-and Treatment-Related Anemia. Version 1.2006. 2006
- National Comprehensive Cancer Network (NCCN). Cancer-and Treatment-Related Anemia Version 3.2007. 2007 [cited July 18, 2007]; Available from: www.nccn.org
- Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083–107
- Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201–16
- Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258–70
- Musto P, Lanza F, Balleari E, Grossi A, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204–9
- Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921–7
- National Comprehensive Cancer Network (NCCN). Myelo-dysplastic Syndromes. Version 1.2007. 2007 [cited March 28, 2007]; Available from: www.nccn.org
- Phrommintikul A, Haas SJ, Elsik M; Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381–8
- United States Food and Drug Administration (FDA). Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). [cited July 18, 2007]; Available from: www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm
- Phurrough S, Jacques L, Ciccanti M, et al. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Center for Medicare and Medicaid Services. July 30, 2007
- Chase M, Matthews A. FDA Warning is a blow to Amgen. Wall Street Journal 2007 March 10, 2007
- Pollack A. FDA Warning is issued on anemia drugs overuse. NY Times, 2007 March 10, 2007
- Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol 2006;24:626–34